Assessing dopaminergic function in Parkinson's disease: Levodopa kinetic-dynamic modeling and SPECT

Journal of Neurology

Volumn 250, Issue 12, 2003, Pages 1475-1481

  Contin, Manuela ^a   Martinelli, Paolo ^a   Riva, Roberte ^a   Dondi, Maurizio ^b   Fanti, Stefano ^c   Pettinato, Cinzia ^c   Scaglione, Cesa ^a   Albani, Fiorenzo ^a   Baruzzi, Agostino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

123I FP CIT SPECT; Levodopa; Parkinson's disease; Pharmacokinetic pharmacodynamic modeling

Indexed keywords

BENSERAZIDE; DOPAMINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HUMAN; ISOTOPE LABELING; KINETICS; MALE; MOLECULAR DYNAMICS; MOLECULAR MODEL; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIPARKINSON AGENTS; BRAIN; COMPUTER SIMULATION; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HALF-LIFE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 1642553301     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0257-3     Document Type: Article

References (25)

1. Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF, Turk MF, Burnett OL (1999) The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's Disease. Mov Disord 14:940-946
2. Baruzzi A, Contin M, Riva R, Albani F (1986) Simple and rapid micromethod for the determination of levodopa and 3-0-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 375:165-169
3. 123I-FP-CIT SPECT striatal uptake. Mov Disord 15:692-698
4. 123I]FPCIT SPECT. J Nucl Med 40:753-761
5. Chang LT (1987) A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 25:638-643
6. Contin, M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: Clinical application in Parkinson's disease. Neurology 43:367-371
7. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1998) A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology 51:1075-1080
8. Contin M, Riva R, Martinelli P, Albani F, Avoni P, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson Disease: A kinetic-dynamic approach. Ther Drug Monit 23:621-629
9. 18F]levodopa positron emission tomography in patients with Parkinson's disease. Clin Pharmacol Ther 70:33-41
10. Fahn S, Elton R, members of the UP-DRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent Developments in Parkinson's Disease. Macmillan Healthcare Information, Florham Park, NJ, pp 153-164
11. Fuseau E, Sheiner LB (1984) Simultaneous modeling of pharmacokinetics and pharmacodynamics with a non-parametric pharmacodynamic model. Clin Pharmacol Ther 35:733-741
12. Gibb WRG, Lees AJ (1988) The relevance of the Lewy body to pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752
13. Gomeni C, Gomeni R (1978) IG-PHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 11:345-361
14. Guttman M. Stewart D, Hussey D, Wilson A, Houle S, Kish S (2001) Influence of L-Dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 56:1559-1564
15. Harder S, Baas H, Rietbrock S (1998) Concentration-response relationship of levodopa in patients at different stages of Parkinson's disease. Clin Pharmacol Ther 64:183-191
16. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 5:427-442
17. Kim SE, Lee WY, Choe YE, Kim JH (1999) SPECT measurement of iodine-123-β-CIT binding to dopamine and serotonin transporters in Parkinson's disease: Correlation with symptom severity. Neurol Res 21:255-261
18. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 318:876-881
19. 123I]beta-CIT. Mov Disord 14:436-442
20. Jaber M, Jones S, Giros B, Caron MG (1997) The dopamine transporter: A crucial component regulating dopamine transmission. Mov Disord 12:629-633
21. Morrish P (2002) Is time to abandon functional imaging in the study of neuroprotection? Mov Disord 17:229-232
22. Powell MD (1964) Methods for finding the minimum of a function of several variables without calculating derivatives. Comp J 7:155-162
23. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371
24. Talairach J, Tournoux P (1988) Co-Planar Stereotactic Atlas of the Human Brain. 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Georg Thieme Verlag, Stuttgart
25. 123I]1PT and single-photon emission tomography. Eur J Nucl Med 24:415-421